

117TH CONGRESS
1ST SESSION

H. R. 349

To direct the Secretary of Health and Human Services to award contracts, grants, and cooperative agreements to expand and enhance capacity for manufacturing covered products to prevent and control the spread of SARS-CoV-2 and COVID-19.

IN THE HOUSE OF REPRESENTATIVES

JANUARY 19, 2021

Ms. KUSTER (for herself and Mr. JEFFRIES) introduced the following bill;
which was referred to the Committee on Energy and Commerce

A BILL

To direct the Secretary of Health and Human Services to award contracts, grants, and cooperative agreements to expand and enhance capacity for manufacturing covered products to prevent and control the spread of SARS-CoV-2 and COVID-19.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Coronavirus Vaccine
5 and Therapeutic Development Act of 2021”.

1 **SEC. 2. COVERED PRODUCT DEVELOPMENT AND PROCURE-**
2 **MENT.**

3 (a) ENHANCING DEVELOPMENT, PROCUREMENT,
4 AND MANUFACTURING CAPACITY.—

5 (1) IN GENERAL.—The Secretary of Health and
6 Human Services shall, as appropriate, award con-
7 tracts, grants, and cooperative agreements, and
8 enter into other transactions—

9 (A) expanding and enhancing covered
10 product research and development;

11 (B) procuring covered products; and

12 (C) expanding and enhancing capacity for
13 manufacturing covered products.

14 (2) AUTHORIZATION OF APPROPRIATIONS.—To
15 carry out this subsection, there is authorized to be
16 appropriated \$20,000,000,000 for fiscal years 2021
17 through 2025, to remain available until expended.

18 (b) REPORT ON VACCINE AND THERAPEUTIC MANU-
19 FACTURING AND ADMINISTRATION CAPACITY.—Not later
20 than December 31, 2021, the Secretary shall submit to
21 the Committee on Energy and Commerce of the House
22 of Representatives and the Committee on Health, Edu-
23 cation, Labor and Pensions of the Senate a report detail-
24 ing—

25 (1) an assessment of the estimated supply of
26 covered products necessary to prevent and control

1 the spread of SARS–CoV–2 and COVID–19, domes-
2 tically and internationally;

3 (2) an assessment of current and future domes-
4 tic manufacturing capacity for covered products, in-
5 cluding identification of any gaps in manufacturing
6 capacity, including—

7 (A) identification of any gaps in capacity
8 for manufacturing; and

9 (B) an analysis of the effects of shifting
10 manufacturing resources to address COVID–19;

11 (3) activities conducted to expand and enhance
12 manufacturing capacity for covered products to lev-
13 els sufficient to prevent and control the spread of
14 SARS–CoV–2 and COVID–19, domestically and
15 internationally, including a list and explanation of
16 all contracts, grants, and cooperative agreements
17 awarded, and other transactions entered into, for
18 purposes of such expansion and enhancement and
19 how such activities will help to meet future domestic
20 manufacturing capacity needs;

21 (4) a plan for the ongoing support of enhanced
22 manufacturing capacity for covered products, domes-
23 tically and internationally; and

24 (5) a plan—

1 (A) to ensure that manufacturing capacity
2 meets the distribution targets and goals of cov-
3 ered products, domestically and internationally;
4 and

5 (B) to support the administration of cov-
6 ered products approved or authorized by the
7 Food and Drug Administration to prevent and
8 control the spread of SARS-CoV-2 and
9 COVID-19, domestically and internationally,
10 including Federal workforce enhancements nec-
11 essary to administer such products.

12 (c) DEFINITIONS.—In this section:

13 (1) The term “ancillary medical supply” in-
14 cludes—

15 (A) vials;

16 (B) bandages;

17 (C) alcohol swabs;

18 (D) syringes;

19 (E) needles;

20 (F) gloves and other personal protective
21 equipment; and

22 (G) other medical products the Secretary
23 determines necessary for the administration of
24 covered products.

1 (2) The term “covered product” means a vac-
2 cine, therapeutic, or ancillary medical supply to pre-
3 vent and control the spread of SARS-CoV-2 and
4 COVID-19.

5 (3) The term “Secretary” means the Secretary
6 of Health and Human Services.

○